Author:
Smith Fraser,Hammerstrom Thomas,Soon Greg,Zhou Susan,Chen Baibai,Mai Yabing,Struble Kimberly,Huque Mohammad
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug guides,Pharmacology (nursing)
Reference9 articles.
1. Chuang-Stcin C. DeMasi R. Surrogate endpoints in AIDS drug development: current status. Drug Inf J. 1998;32:439–448.
2. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998; 177:40–47.
3. Hill AM, DeMasi R. Dawson D. Meta-analysis of antiretroviral effects on HIV-1 RNA. CD4 cell count and progression to AIDS or death. Antiviral Ther. 1998;3:139–145.
4. Division of Antiviral Drug Products. Office of Drug Evaluation IV. Center for Drug Evaluation and Research. Food and Drug Administration. Guidance for industry. Antiretroviral drugs using plasma HIV RNA measurements—clinical considerations for accelerated and traditional approval. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRcgulatoryInformation/Guidances/ucm070968.pdf.
5. Murray JS. Elashoff MR. lacono-Connors LC, et al. The use of plasma HIV RNA as a study end-point in efficacy trials of antiretroviral drugs. AIDS. 1999;13:797–804.
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz–Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study;Open Forum Infectious Diseases;2023-11-20
2. Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials;HIV Medicine;2022-08-17
3. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial;The Lancet Child & Adolescent Health;2021-09
4. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon;The Lancet HIV;2020-10
5. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus;Clinical Infectious Diseases;2020-07-15